Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.78 |
| ▸ | HPGD | P15428 | 7/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | CA12 | O43570 | 1/20 | 0.78 |
| ▸ | CA1 | P00915 | 1/20 | 0.78 |
| ▸ | CA2 | P00918 | 1/20 | 0.78 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.78 |
| ▸ | CA4 | P22748 | 1/20 | 0.78 |
| ▸ | CA6 | P23280 | 1/20 | 0.78 |
| ▸ | CA7 | P43166 | 1/20 | 0.78 |
| ▸ | CA9 | Q16790 | 1/20 | 0.78 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.78 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | G6PD | P11413 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL28313591 | 0.91 | ALDH1A1 (0.95) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL28222899 | 0.91 | ALDH1A1 (0.95) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL17156443 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29360246 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29606432 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1967 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1509155 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29362663 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL8433746 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1062720 | 0.86 | ALDH1A1 (0.95) | ALDH1A1HPGDKDM4ESMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366573-A1 | OINTMENT CONTAINING AN OXAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| US-20220117944-A1 | OINTMENT CONTAINING AN OXAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-04-21 | — | — | US | disclosed |
| US-20200171006-A1 | OINTMENT CONTAINING AN OXAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-04 | — | — | US | disclosed |
| US-10588893-B2 | Ointment containing an oxazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-17 | — | — | US | disclosed |
| US-20190000810-A1 | OINTMENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-03 | — | — | US | disclosed |
| EP-3397619-A1 | OINTMENT | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-11-07 | — | — | EP | disclosed |
| WO-2017115780-A1 | OINTMENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366573-A1 | OINTMENT CONTAINING AN OXAZOLE COMPOUND | PDE12, PDE4B, PDE4A | ALDH1A1 100/4885HPGD 707/4885KDM4E 735/4885 |
| US-20200171006-A1 | OINTMENT CONTAINING AN OXAZOLE COMPOUND | PDE12, PDE4B, PDE4A | ALDH1A1 100/4885HPGD 707/4885KDM4E 735/4885 |
| US-20220117944-A1 | OINTMENT CONTAINING AN OXAZOLE COMPOUND | PDE12, PDE4B, PDE4A | ALDH1A1 100/4885HPGD 707/4885KDM4E 735/4885 |
| US-10588893-B2 | Ointment containing an oxazole compound | PDE12, PDE4B, PDE4A | ALDH1A1 100/4885HPGD 707/4885KDM4E 735/4885 |
| US-20190000810-A1 | OINTMENT | PDE12, PDE4B, PDE4A | ALDH1A1 67/4885HPGD 543/4885KDM4E 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.